TSTickerStarGet alerts
Company alerts/EYPT
EYPT company alerts

EYPT updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for EYPT. Subscribe to EYPT alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for EYPT alertsView companies
Official-source feed

Recent EYPT alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

EyePoint Announces 53% Workforce Reduction After Phase 3 LUCIA Trial Misses Primary Endpoint in Wet AMD

EyePoint announced a strategic prioritization plan following topline results from the Phase 3 LUCIA trial of DURAVYU in wet AMD, which did not meet its primary endpoint of non-inferiority despite meeting key secondary endpoints including reduction in treatment burden, supplement-free rates, anatomic control, and safety with redosing. The Board approved a plan to reduce the workforce by approximately 53%, conclude the pivotal Phase 3 wet AMD trials early, and refocus resources on the DURAVYU program in diabetic m...

Read source-backed brief
Company newsOfficial company source

EyePoint announces LUCIA Phase 3 topline data: primary endpoint missed, secondary endpoints met

EyePoint reported topline data from the LUCIA Phase 3 trial of DURAVYU in wet AMD, which did not achieve the primary endpoint of non-inferiority in mean change in BCVA versus on-label aflibercept (DURAVYU +2.5 letters vs. aflibercept +6.1 letters; difference -3.7 letters). Key secondary endpoints were met, including a 38% reduction in treatment burden (nominal p<0.0001), 52% supplement-free rate and 71% zero-or-one supplement rate through Week 56, with continued favorable safety. LUGANO, the first pivotal Phase...

Read source-backed brief